重组人促红细胞生成素不同给药途径对血液透析患者的疗效观察  

Curative Effect of Recombinate Erythropoietin Administered by Different Routes for Patients Receiving Hemodialysis

作　　者：何智义[1] 吴艳萍[1] 刘春梅[2] 蒲涛[2] 

机构地区：[1]遵义医学院第一附属医院药剂科,遵义市563003 [2]遵义医学院第一附属医院肾内科,遵义市563003

出　　处：《中国药房》2009年第23期1799-1801,共3页China Pharmacy

摘　　要：目的:了解重组人促红细胞生成素(r-HuEPO)在不同给药途径下的临床疗效。方法:40例维持性血液透析(MHD)患者随机分为皮下和静脉注射组,观察12周内血红蛋白(Hb)、血细胞比容(Hct)的变化及不良反应。结果:随着治疗时间的延长,2组患者的Hb、Hct均呈上升趋势,治疗后第8周、第12周较治疗前均有显著性升高(P<0.05),但皮下注射组升高较静脉注射组有显著性差异(P<0.05),皮下注射组高血压出现更少(P<0.05)。结论:r-HuEPO使用皮下注射效果更好,副作用较小。OBJECTIVE： To evaluate the curative efficacy of recombinate erythropoietin （r-HuEPO） administered through different route for patients receiving hemodialysis. METHODS： 40 patients undergoing maintenance hemodialysis （MHD） were randomized into subcutaneous injection group and intravenous injection group. The hemoglobin （Hb）, hematokrit （Hct） and the adverse effect within 12 weeks were observed. RESULTS： The Hb/Hct level of the two groups increased with the prolonging of treatment, which increased significantly at 8 weeks and 12 weeks as compared with before treatment（P〈 0.05） and the differences between the subcutaneous injection group and the intravenous injection group were significant（P〈 0.05）. The incidence of hypertension was less in subcutaneous injectiongroup than in intravenous injection group （P 〈 0.05）. CONCLUSION： r-HuEPO showed better efficacy and fewer adverse effects in subcutaneous injection group than in intravenous injection group.

关 键 词：血液透析 重组人促红细胞生成素 皮下注射 静脉注射 高血压 

分 类 号：R969.4[医药卫生—药理学]